Across TCGA pan-cancer cohorts, SELENOW Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SELENOW data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SELENOW Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SELENOW expression acts as an unfavorable survival marker.
COAD and SKCM are the cancer types where SELENOW Mutation most reproducibly stratifies survival.